By Ian Ingram
Benefit seen across all subgroups for patients with platinum-sensitive disease.
Ovarian cancer patients with recurrent, platinum-sensitive disease experienced a longer interval without disease progression when bevacizumab (Avastin) was added to niraparib (Zejula), a phase II study found.… Read more
Under the Affordable Care Act (ACA), women with ovarian cancer were more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis, according to researchers at Johns Hopkins School of Medicine, … Read more
By
Helpful advice from experts and a mom who’s been there twice.
When you’re diagnosed with cancer, processing it is hard, and figuring out how to tell your kids about it just adds to the stress and … Read more
Patients with ovarian cancer who experience disease recurrences can have potentially helpful options from a large array of drugs, each of which can bring on side effects.
Luckily, doctors have a variety of ways to relieve or prevent these discomforts.
… Read moreBy Kelly Irvin
A second ovarian cancer recurrence in three years prompted this review of lessons learned. If I could go back three and a half years and give advice to my newly diagnosed self, what would I say?
This … Read more
By Sarah Elizabeth Richards
Photo: Liz Laats with husband Andy Laats and their three children. She died three years ago of ovarian cancer. The San Diego resident had suffered through 88 rounds of chemotherapy during 10 treatment regimens over six … Read more
In what they claim is the first large-scale systematic analysis of thousands of gene fusions in human cancers, scientists have identified a gene fusion that could represent a novel drug target for multiple cancers. Through their studies, the largely U.K.-based … Read more
According to researchers at Yale Cancer Center, a cancer drug thought to be of limited use possesses a superpower of sorts: It is able to stop certain cancer cells from repairing their DNA in order to survive. The study, published … Read more
By Jessica Kent
A system-based intervention reduced racial disparities among black and white cancer patients.
A pragmatic, system-based intervention decreased racial disparities in cancer treatment and outcomes for black patients with early-stage breast cancer.
In a five-year study conducted at … Read more
By Michael Brown
Oncologists may soon have an accurate and inexpensive way of differentiating between types of ovarian cancer that will improve how patients are treated, thanks to findings from a national research study co-led out of the University of … Read more
By Sarah Elizabeth Richards
Photo: Diagnosed with terminal metastatic breast cancer, Tori Geib started seeing a palliative care coach in Columbus, Ohio. She says the treatment helped improve the quality of her life. (Matt Vojacek)
When Tori Geib learned she … Read more
By Kristin Jenkins
The presence of a BRCA germ line mutation in patients with invasive epithelial ovarian cancer may confer a short-term survival advantage, but is not associated with a reduction in long-term mortality, researchers found.
A follow-up study comparing … Read more
DNA shed by tumors into the bloodstream is starting to be used for the early detection of cancer and for monitoring how well treatment is working. Such DNA, which is called circulating tumor DNA (ctDNA), hasn’t been quite as helpful
… Read moreA gynecologic oncologist at the Stephenson Cancer Center at OU Medicine was a national leader of a newly published research study that reveals good news for women with ovarian cancer—longer survival times plus a treatment option that causes fewer difficult … Read more
A team of researchers at UCLA’s Jonsson Comprehensive Cancer, Cedars-Sinai Cancer and Dana-Farber Cancer Institute have newly identified 34 genes that are associated with an increased risk for developing the earliest stages of ovarian cancer. The findings, published today in … Read more
By Dr. Leslie Boyd
Ovarian cancer produces the type of tumor that oncologists like to call “chemo-sensitive”—which is pretty good news for anyone diagnosed. Ovarian cancer cells have been shown to respond well to a combination of chemo drugs, which … Read more
A systematic examination of the tumor and the tissue surrounding it—particularly normal cells in that tissue, called fibroblasts—has revealed a new treatment target that could potentially prevent the rapid dissemination and poor prognosis associated with high-grade serous carcinoma (HGSC), a … Read more
Two of the key points this article touches on refer to finding a clinical trial and seeking mental health support. At Clearity, we can help! Check out our Clinical Trial Finder, as well as Steps Through OC, a … Read more
Given that the limited number of patients and differences in biologic behavior pose challenges in conducting clinical trials in rare malignancies, researchers determined whether using genomic profiling for rare gynecologic malignancies is feasible and have clinical utility. They analyzed somatic
… Read more
